Loading…
PGNY
Progyny, Inc.
NASDAQ· Healthcare· Healthcare Plans
$26.00+0.54%
Key metrics
- Market cap
- $1.99B
- P/E
- 28.3x
- Forward P/E
- 11.2x
- P/B
- 4.4x
- Dividend yield
- —
- EPS
- $0.92
- ROE
- 16.24%
- Profit margin
- 6.00%
- Revenue growth
- +5.30%
- Beta
- 1.02
- 52-week high
- $33.07
- 52-week low
- $16.10
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
- 835
- New York, United States
Company description provided by Yahoo Finance.
